FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W20224748> ?p ?o ?g. }

• W20224748 endingPage "1629" @default.
• W20224748 startingPage "1622" @default.
• W20224748 abstract "Purpose To determine the clinical efficacy and safety of moxifloxacin (1.0%) in patients with bacterial keratitis compared with patients treated with ofloxacin (0.3%) or fortified tobramycin (1.33%)/cephazolin (5%). Design Prospective randomized trial. Participants A total of 229 patients diagnosed with bacterial keratitis were enrolled in the study; 78 patients were randomized to the fortified tobramycin/cephazolin group, 77 patients to the moxifloxacin group, and 74 patients to the ofloxacin group. A total of 225 patients were evaluable for safety and 198 patients were included in the efficacy analysis. Intervention After corneal specimens were obtained, the assigned study medication was instilled every hour, day and night, for 48 hours and on the third day, every hour by day and every 2 hours at night. For days 4 and 5, 1 drop every 2 hours by day and every 4 hours at night, and for days 6 and 7, 1 drop every 4 hours. After day 7, the antibiotic was tapered to every 6 hours and stopped when appropriate. Main Outcome Measures Resolution of keratitis and healing of ulcer, time to cure, mean time to discharge, clinical sign score, adverse reactions to study medication, and treatment failures. Results Of the 186 nonexiting patients, resolution of the keratitis and healing of the ulcer occurred in 175 (94%) nonexiting patients. In the 175 patients in whom the corneal ulcer was cured, there were no statistically significant differences between the treatment groups for the mean time to cure (P = 0.25). There were no statistically significant differences between the 3 treatment groups in the various sign parameters including the sign score. A positive bacterial corneal culture was obtained in 190 (83%) of the 229 enrolled patients. The distribution of the species of bacterial organisms was similar in each treatment group and no significant difference in the percentage of isolates between the groups was observed. Twelve (5.2%) of the treated patients had serious complications (perforation or enucleation). No serious events attributable to therapy occurred during the study and all treatments were safe and well tolerated. Conclusion No difference in healing rate, cure rate, or complications between fortified cephazolin and tobramycin, ofloxacin, or moxifloxacin was seen in this study. To determine the clinical efficacy and safety of moxifloxacin (1.0%) in patients with bacterial keratitis compared with patients treated with ofloxacin (0.3%) or fortified tobramycin (1.33%)/cephazolin (5%). Prospective randomized trial. A total of 229 patients diagnosed with bacterial keratitis were enrolled in the study; 78 patients were randomized to the fortified tobramycin/cephazolin group, 77 patients to the moxifloxacin group, and 74 patients to the ofloxacin group. A total of 225 patients were evaluable for safety and 198 patients were included in the efficacy analysis. After corneal specimens were obtained, the assigned study medication was instilled every hour, day and night, for 48 hours and on the third day, every hour by day and every 2 hours at night. For days 4 and 5, 1 drop every 2 hours by day and every 4 hours at night, and for days 6 and 7, 1 drop every 4 hours. After day 7, the antibiotic was tapered to every 6 hours and stopped when appropriate. Resolution of keratitis and healing of ulcer, time to cure, mean time to discharge, clinical sign score, adverse reactions to study medication, and treatment failures. Of the 186 nonexiting patients, resolution of the keratitis and healing of the ulcer occurred in 175 (94%) nonexiting patients. In the 175 patients in whom the corneal ulcer was cured, there were no statistically significant differences between the treatment groups for the mean time to cure (P = 0.25). There were no statistically significant differences between the 3 treatment groups in the various sign parameters including the sign score. A positive bacterial corneal culture was obtained in 190 (83%) of the 229 enrolled patients. The distribution of the species of bacterial organisms was similar in each treatment group and no significant difference in the percentage of isolates between the groups was observed. Twelve (5.2%) of the treated patients had serious complications (perforation or enucleation). No serious events attributable to therapy occurred during the study and all treatments were safe and well tolerated. No difference in healing rate, cure rate, or complications between fortified cephazolin and tobramycin, ofloxacin, or moxifloxacin was seen in this study." @default.
• W20224748 created "2016-06-24" @default.
• W20224748 creator A5013180301 @default.
• W20224748 creator A5036079276 @default.
• W20224748 creator A5040022343 @default.
• W20224748 creator A5056449225 @default.
• W20224748 creator A5061770507 @default.
• W20224748 date "2007-09-01" @default.
• W20224748 modified "2023-10-15" @default.
• W20224748 title "Clinical Efficacy of Moxifloxacin in the Treatment of Bacterial Keratitis" @default.
• W20224748 cites W1483931223 @default.
• W20224748 cites W1998973585 @default.
• W20224748 cites W2001675818 @default.
• W20224748 cites W2006698976 @default.
• W20224748 cites W2007489189 @default.
• W20224748 cites W2011172868 @default.
• W20224748 cites W2016037072 @default.
• W20224748 cites W2026281986 @default.
• W20224748 cites W2030162048 @default.
• W20224748 cites W2030185059 @default.
• W20224748 cites W2038621973 @default.
• W20224748 cites W2047055639 @default.
• W20224748 cites W2067486533 @default.
• W20224748 cites W2081842859 @default.
• W20224748 cites W2082205722 @default.
• W20224748 cites W2083540127 @default.
• W20224748 cites W2094808300 @default.
• W20224748 cites W2096255649 @default.
• W20224748 cites W2108064520 @default.
• W20224748 cites W2109203736 @default.
• W20224748 cites W2126489219 @default.
• W20224748 cites W2131902898 @default.
• W20224748 cites W2135888335 @default.
• W20224748 cites W2139314102 @default.
• W20224748 cites W2147253907 @default.
• W20224748 cites W2155930383 @default.
• W20224748 cites W2161947080 @default.
• W20224748 cites W2436190484 @default.
• W20224748 cites W4230898039 @default.
• W20224748 doi "https://doi.org/10.1016/j.ophtha.2006.12.011" @default.
• W20224748 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17822972" @default.
• W20224748 hasPublicationYear "2007" @default.
• W20224748 type Work @default.
• W20224748 sameAs 20224748 @default.
• W20224748 citedByCount "94" @default.
• W20224748 countsByYear W202247482012 @default.
• W20224748 countsByYear W202247482013 @default.
• W20224748 countsByYear W202247482014 @default.
• W20224748 countsByYear W202247482015 @default.
• W20224748 countsByYear W202247482016 @default.
• W20224748 countsByYear W202247482017 @default.
• W20224748 countsByYear W202247482019 @default.
• W20224748 countsByYear W202247482020 @default.
• W20224748 countsByYear W202247482021 @default.
• W20224748 countsByYear W202247482022 @default.
• W20224748 countsByYear W202247482023 @default.
• W20224748 crossrefType "journal-article" @default.
• W20224748 hasAuthorship W20224748A5013180301 @default.
• W20224748 hasAuthorship W20224748A5036079276 @default.
• W20224748 hasAuthorship W20224748A5040022343 @default.
• W20224748 hasAuthorship W20224748A5056449225 @default.
• W20224748 hasAuthorship W20224748A5061770507 @default.
• W20224748 hasConcept C118487528 @default.
• W20224748 hasConcept C126322002 @default.
• W20224748 hasConcept C141071460 @default.
• W20224748 hasConcept C168563851 @default.
• W20224748 hasConcept C197934379 @default.
• W20224748 hasConcept C2775832221 @default.
• W20224748 hasConcept C2778049240 @default.
• W20224748 hasConcept C2778353156 @default.
• W20224748 hasConcept C2778512257 @default.
• W20224748 hasConcept C2778560704 @default.
• W20224748 hasConcept C2778836808 @default.
• W20224748 hasConcept C2778974779 @default.
• W20224748 hasConcept C42219234 @default.
• W20224748 hasConcept C501593827 @default.
• W20224748 hasConcept C535046627 @default.
• W20224748 hasConcept C71924100 @default.
• W20224748 hasConcept C86803240 @default.
• W20224748 hasConcept C89423630 @default.
• W20224748 hasConceptScore W20224748C118487528 @default.
• W20224748 hasConceptScore W20224748C126322002 @default.
• W20224748 hasConceptScore W20224748C141071460 @default.
• W20224748 hasConceptScore W20224748C168563851 @default.
• W20224748 hasConceptScore W20224748C197934379 @default.
• W20224748 hasConceptScore W20224748C2775832221 @default.
• W20224748 hasConceptScore W20224748C2778049240 @default.
• W20224748 hasConceptScore W20224748C2778353156 @default.
• W20224748 hasConceptScore W20224748C2778512257 @default.
• W20224748 hasConceptScore W20224748C2778560704 @default.
• W20224748 hasConceptScore W20224748C2778836808 @default.
• W20224748 hasConceptScore W20224748C2778974779 @default.
• W20224748 hasConceptScore W20224748C42219234 @default.
• W20224748 hasConceptScore W20224748C501593827 @default.
• W20224748 hasConceptScore W20224748C535046627 @default.
• W20224748 hasConceptScore W20224748C71924100 @default.
• W20224748 hasConceptScore W20224748C86803240 @default.
• W20224748 hasConceptScore W20224748C89423630 @default.

• next